Propranolol in acute intermittent porphyria

Area of Science:

• Cardiology
• Neurology
• Pharmacology

Background:

• Acute intermittent porphyria (AIP) is a rare genetic disorder.
• Cardiovascular manifestations, including tachycardia and hypertension, are common during AIP acute phases.
• Effective management of these cardiovascular symptoms is crucial for patient outcomes.

Purpose of the Study:

• To investigate the efficacy of propranolol in managing cardiovascular manifestations in patients with acute intermittent porphyria.
• To assess the long-term effects of propranolol on heart rate, blood pressure, and AIP attack prevention.

Main Methods:

• A study of twenty AIP cases during the acute phase.
• Administration of propranolol (20-200 mg) to all patients.
• Monitoring of cardiovascular parameters (heart rate, blood pressure) and AIP attack frequency.

Main Results:

• All twenty cases exhibited cardiovascular manifestations, with 100% experiencing tachycardia and 85% experiencing hypertension.
• Propranolol effectively controlled both tachycardia and hypertension in all patients.
• Smaller maintenance doses of propranolol at follow-up normalized pulse rate and blood pressure and prevented acute AIP attacks.

Conclusions:

• Propranolol is an effective treatment for managing acute cardiovascular complications in acute intermittent porphyria.
• Long-term, low-dose propranolol therapy can maintain cardiovascular stability and reduce the recurrence of AIP attacks.